Amgen readies PhIII trial for first Opdivo biosimilar, with launch unlikely before 2028

The race to end Bristol Myers Squibb’s exclusivity on its megablockbuster cancer drug Opdivo (nivolumab) is beginning in earnest, with Amgen looking to kick off a Phase III trial next month for its potential biosimilar to the drug.

The randomized, double-blind trial aims to enroll 620 participants and evaluate the…
Click here to view original post